Expression of chemokine receptors in angiosarcoma

Tomoo Kishi, Yuki Yamamoto, Chikako Kaminaka, Seiko Toyozawa, Hiroshi Matsunaka, Fukumi Furukawa


Angiosarcoma is a rapidly progressing malignant skin tumor associated with a poor prognosis. We report an immunohistochemical investigation of chemokine receptors in angiosarcoma. The aim is to investigate chemokine receptor expression and, if it is expressed, to histologically discuss its association with age, sex, development site, and histological type. Analyzed were 12 angiosarcoma samples (mean patient age: 75.7 years old) collected by biopsy or surgery from patients at our department by comparing with 4 granuloma telangiectaticum samples (mean patient age: 37.5 years old) and 16 healthy skin samples as controls. CXCR4, CCR6, CCR7, and SDF-1 expressions were immunohistochemically investigated. CXCR4 expression was positive in 6 of the 12 samples. CCR6 and CCR7 were negative in all samples. SDF-1 was positive in 4 samples. Out of the 6 CXCR4-positive samples, 4 were SDF-1-positive. No significant difference associated with age, sex, development site, or histological type was noted in the expression of CXCR4, CCR6, CCR7, or SDF-1. Although CXCR4 is regarded as an index of tumor aggressiveness of malignant melanoma, it is suggested that chemokine receptors, such as CXCR4, do not serve as useful markers of angiosarcoma.


CXCR4; chemokine receptor; angiosarcoma; immunohistochemistry

Full Text:



Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D (editors). Rook’s textbook of dermatology. 9th ed. Oxford, UK: Wiley-Blackwell; 2016. p. 137.36-38.

Zlotnik A. Chemokines and cancer. Int J Cancer 2006; 119(9); 2026–2029. doi: 10.1002/ijc.22024.

Müller A, Homey B, Soto H, Ge N, Catron D, et al. Involvement of chemokine receptor in breast cancer metastasis. Nature 2001; 410(6824): 50–56. doi: 10.1038/35 065016.

Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11(5): 1835–1841. doi: 10.1158/1078-0432.CCR-04-18 87.

Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, et al. Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy. Int J Cancer 2006; 118(9): 2147–2157. doi: 10.1002/ijc.21514.

Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 2009; 15(9): 2962–2970. doi: 10.1158/1078-0432.CCR-08-2495.

Wang J, Xi L, Hunt JL, Gooding W, Whiteside TL, et al. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 2004; 64(5): 1861–1866. doi: 10.1158/0008-5472.CAN-03-29 68.

Toyozawa S, Yamamoto Y, Ishida Y, Kondo T, Nakamura Y, et al. Immunohistochemical analysis of CXCR4 expression in fibrohistiocytic tumors. Acta Histochem Cy-tochem 2010; 43(2): 45–50. doi: 10.1267/ahc.10003.

Toyozawa S, Kaminaka C, Furukawa F, Nakamura Y, Matsunaka H, et al. Chemokine receptor CXCR4 is a novel marker for the progression of cutaneous malignant melanomas. Acta Histochem Cytochem 2012; 45(5): 293–299. doi: 10.1267/ahc.12004.

Nakatsugawa S. 舌扁平上皮癌におけるSDF-1/CXCR4 発現と臨床病理的因子との関連について(Japanese) [On the relationship between SDF-1/CXCR4 expression and clinicopathological factors in squamous cell carcinoma of the tongue]. Dokkyo J Med Sci 2012; 39(1): T1–T11.

Elder DE. In: Elenitsas R, Johnson Jr BL, Murphy GF, Xu X, (editors). Lever’s histopathology of the skin. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 1040–1043.

Kaminaka T, Toyozawa S, Yoshi Y, Kunimoto K, Furukawa F, et al. フェノールによる日光角化症とボーエン病の治療効果とケモカインレセプターに関する免疫組織化学的検討 (Japanese) [Phenol peels for the treatment of actinic keratosis and Bowen’s disease: Correlation with chemokine receptors expression]. Skin Cancer 2011; 26(3): 327–332. doi: 10.5227/skincanc er.26.327.


  • There are currently no refbacks.